Association between serum leptin levels and peritoneal dialysis: A meta-analysis

Jiang, Shan; Song, Kai; Feng, Sheng; Shi, Yong‐Bin

doi:10.3892/etm.2015.2441

Cited by 6 publications

(6 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results support recent studies regarding the importance of leptin levels in PD patients. As well as the majority of previous studies [9,[16][17][18][19] the results of our study have demonstrated an increasing level of serum leptin concentration in ESRD patients after PD treatment initiation. Teda D et al showed that a single 6-h dwell with PD4 3.86% glucose acutely increased plasma leptin level [20].…”

supporting

confidence: 86%

“…Distinctively ever-increasing serum leptin level in overweight PD patients can be a consequence of altered glucose and fat metabolism which may lead to chronic inflammation, malnutrition and low long-term survival of the patients [17,18]. On the other hand, hyperleptinemia is reported as the phenomenon of "Reverse Epidemiology" or "Obesity Paradox" in patients with ESRD [22,23].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Baseline serum leptin predicts peritoneal dialysis adequacy: a single-center prospective, longitudinal study

Stepanova

Burdeyna

Driianska

et al. 2018

Ukr. Journ. Nephrol. and Dial.

View full text Add to dashboard Cite

Hyperleptinemia is often observed in peritoneal dialysis (PD) patients. But, there are few studies on the relationship between blood leptin level and PD survival, and, some of them contradict each other. The present study aimed to investigate the impact of PD initiation on the serum leptin concentrations and its association with PD adequacy. Method. A total of 23 patients with end-stage renal disease (ESRD), who started the treatment with continuous ambulatory peritoneal dialysis (CAPD), were included in this prospective single-center observational longitudinal study. Among the patients, there were 15 men and 8 women; the average age of the patient population was 52.4 ± 12.3 years. The treatment with CAPD was performed using Dianeal PD 4 with glucose concentration of 1.36% and 2.27%. The patients were screened before PD initiation and after 3- and 12- month PD treatment. Leptin levels were determined in all patients using ELISA-method. Results. The median serum leptin concentration at study entry was 10.6 [5.6-21.9] ng/mL. Leptin level and its dynamics during the year after PD treatment initiation were dependent on body mass index (BMI). The overweight or obese patients had ever-increasing leptin levels after 3- and 12- month PD treatment. Whereas in the PD patients with normal weight, we observed a significant decrease of leptin levels after 12-month PD treatment. Serum leptin concentration in the women was significantly higher compared with the men (46.4 [1.1-95] vs 9.8 [3.2-14.5] ng/mL; p = 0.02). Blood cholesterol levels had a positive correlation with serum leptin concentrations after 3- and 12- month PD treatment: r = 0.53, p = 0.01 and r = 0.56, p = 0.008, respectively. However, we did not find a statistically significant association of leptin with PD adequacy parameters after 3- and 12- month PD treatment of the patients. In the Cox proportional hazard model adjusted for gender, serum leptin level demonstrated itself as the effective factor in PD adequacy survival: HR 5.3 (95% CI 1.7; 16.3). PD adequacy survival was better in the patients with leptin concentrations above the median (≥10.6 ng/mL) compared with the patients who had serum leptin levels below the median (log rank test, χ2 = 8.2; p = 0.0042). Conclusions. Our study have demonstrated markedly elevated serum leptin level in the overweight PD patients and its strong decrease during 12 months in the patients with normal weight. Low serum leptin level before PD initiation is associated with inadequate PD.

show abstract

supporting

confidence: 86%

mentioning

confidence: 99%

Baseline serum leptin predicts peritoneal dialysis adequacy: a single-center prospective, longitudinal study

Stepanova

Burdeyna

Driianska

et al. 2018

Ukr. Journ. Nephrol. and Dial.

View full text Add to dashboard Cite

show abstract

“…The glucose concentration of different dialysis buffers may impact the burden of kidney filtration rate [11]. Studies have shown that the glucose concentration also promotes peritoneal inflammation and the production of transforming growth factor by peritoneal mesothelial cells, finally leading to fibrosis [12]. Therefore, peritoneal dialysis combined with FIR can reduce the side effects of glucose in dialysis buffer, which interferes with peritoneal inflammation and peritoneal mesothelial cell fibrosis.…”

Section: The Physiological Effect Of Peritoneal Dialysis Due To Firmentioning

confidence: 99%

“…Glucose degradation products (GDPs) contribute to reduced dialysis function and the pathogenesis of peritoneal membrane fibrosis [8,9,10]. A previous study showed that long-term exposure to non-biocompatible high-concentration glucose dialysate and repeated peritonitis are the main causes of changes in the structure and function of the peritoneum [4,11,12]. In summary, these factors induce proinflammatory hormones, such as interleukin-l beta (IL-1β), interleukin(IL), and tumor necrosis factor alpha (TNF-α), which triggers a persistent inflammatory response in the peritoneum, ultimately leading to structural changes in the peritoneum [13,14,15,16].…”

Section: Introductionmentioning

confidence: 99%

Does Far-Infrared Therapy Improve Peritoneal Function and Reduce Peritonitis Recurrent in Peritoneal Dialysis Patients?

Chang¹,

Chang²,

Lee³

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: The treatment of peritoneal dialysis in end-stage renal disease is increasing in clinical practice. The main purpose of this study was to evaluate the effect of far-infrared radiation therapy on inflammation and the cellular immunity of patients undergoing peritoneal dialysis. Materials and Methods: We recruited 56 patients undergoing peritoneal dialysis, and we included 32 patients from the experimental group and 24 patients from the control group in the final analysis. The experimental evaluation in our study was as follows: (1) We used abdominal computed tomography to measure the diameter and degree of hardening of the abdominal veins and large blood vessels to explore the changes in abdominal blood vessels. (2) The study compared the effects of peritoneal dialysis using albumin, blood urea nitrogen, creatinine, white blood cell, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, erythrocyte sedimentation rate, Hs-CRP clearance rate, and HBAlC. (3) We compared the cytokine concentration of blood between the two groups while controlling for GM-CSF, IL-2, IFN-γ, IL-6, IL-18, IL-4, IL-5, IL-13, IL-12p70, TNF-α, and IL-1β. Results and Discussion: (1) There was no significant difference in the abdominal blood vessels of the experimental group relative to the control group according to abdominal CT measured over 6 months. (2) Our study demonstrates the statistically significant effect of FIR therapy on the following parameters: albumin (p = 0.048*), creatinine (p = 0.039*), and Hs-CRP (p < 0.001**) decreased significantly, and glomerular filtration rate (eGFR, p = 0.043*) and glucose (p < 0.001**) increased significantly. Our study found that, in the experimental group, albumin and creatinine decreased significantly due to FIR therapy for 6 months. However, our study also found that, in the experimental group, glucose (p < 0.001**) increased significantly due to FIR therapy for 6 months. Peritoneal dialysis combined with FIR can reduce the side effects of glucose in dialysis buffer, which interferes with peritoneal inflammation and peritoneal mesothelial cell fibrosis. In addition, we also found that, in the experimental group, Hs-CRP (p < 0.001**) decreased significantly due to FIR therapy for 6 months. (3) No statistical significance in the inflammatory cytokines related to FIR therapy differences was observed in our study. IFN-γ (p = 0.124), IL-12p70 (p = 0.093), IL-18 (p = 0.213), and TNF-α (p = 0.254) did not exhibit significant improvements in peritoneal dialysis with FIR treatment over 6 months. IFN-γ and IL-18 in the plasma of patients in the experimental group and the control group were higher in the third month than in the first month. Conclusion: We found that the effect of peritoneal dialysis improved significantly with FIR therapy, and significant improvements in the peritoneal permeability and inflammatory response were observed. end-stage renal disease; peritoneal dialysis; far-infrared therapy (FIR)

show abstract

“…Glucose degradation products (GDPs) contribute to reduced dialysis function and the pathogenesis of peritoneal membrane fibrosis [ 8 , 9 , 10 ]. A previous study showed that long-term exposure to non-biocompatible high-concentration glucose dialysate and repeated peritonitis are the main causes of changes in the structure and function of the peritoneum [ 4 , 11 , 12 ]. During an acute inflammatory process such as peritonitis, natural killer (NK) cells produce inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin (IL-6).…”

Section: Introductionmentioning

confidence: 99%

Does Far-Infrared Therapy Improve Peritoneal Function and Reduce Recurrent Peritonitis in Peritoneal Dialysis Patients?

Chang

Chang²,

Lee

et al. 2022

JCM

View full text Add to dashboard Cite

The use of peritoneal dialysis in end-stage renal disease is increasing in clinical practice. The main purpose of this study was to evaluate the effect of far-infrared radiation therapy on inflammation and the cellular immunity of patients undergoing peritoneal dialysis. We recruited 56 patients undergoing peritoneal dialysis, and we included 32 patients for the experimental group and 24 patients from the control group in the final analysis. The experimental evaluation in our study was as follows: (1) We used abdominal computed tomography to explore the changes in abdominal blood vessels. (2) We compared the effects of peritoneal dialysis using blood glucose, HbAlC, albumin, urea nitrogen, creatinine, white blood cells, hs-CRP; peritoneal Kt/V of peritoneal function, and eGFR. (3) We compared the cytokines’ concentrations in the two groups while controlling for the other cytokines. Results and Discussion: (1) There was no significant difference in the abdominal blood vessels of the experimental group relative to the control group according to abdominal CT over the 6 months. (2) Our study demonstrates statistically significant effects of FIR therapy on the following parameters: creatinine (p = 0.039 *) and hs-CRP (p < 0.001 **) levels decreased significantly, and eGFR (p = 0.043 *), glucose (p < 0.001 **), and albumin (p = 0.048 *) levels increased significantly. Our study found that in the experimental group, creatinine and hs-CRP levels decreased significantly due to FIR therapy for 6 months. However, our study also found that the glucose level was significantly different after FIR therapy for 6 months. Peritoneal dialysis combined with FIR can reduce the side effects of the glucose in the dialysis buffer, which interferes with peritoneal inflammation and peritoneal mesothelial cell fibrosis. (3) In addition, we also found that no statistically significant difference in any inflammatory cytokine after FIR therapy. IFN-γ (p = 0.124), IL-12p70 (p = 0.093), IL-18 (p = 0.213), and TNF-α (p = 0.254) did not exhibit significant improvements after peritoneal dialysis with FIR treatment over 6 months. Conclusions: We found that the effectiveness of peritoneal dialysis was improved significantly with FIR therapy, and significant improvements in the peritoneal permeability and inflammatory response were observed.

show abstract

Association between serum leptin levels and peritoneal dialysis: A meta-analysis

Cited by 6 publications

References 47 publications

Baseline serum leptin predicts peritoneal dialysis adequacy: a single-center prospective, longitudinal study

Baseline serum leptin predicts peritoneal dialysis adequacy: a single-center prospective, longitudinal study

Does Far-Infrared Therapy Improve Peritoneal Function and Reduce Peritonitis Recurrent in Peritoneal Dialysis Patients?

Does Far-Infrared Therapy Improve Peritoneal Function and Reduce Recurrent Peritonitis in Peritoneal Dialysis Patients?

Contact Info

Product

Resources

About